VivoSeq
Other

Preeclampsia

94

Pipeline Programs↗

41

Active Trials↗

46

Companies Involved↗

Preeclampsia is a moderately active landscape with 94 programs across 46 companies. The most active players are Comanche Biopharma, Merck & Co., La Jolla Pharmaceutical Company. 33 therapies are approved with 16 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

71/100

Pipeline Velocity

39/100

Mech. Concentration

7/100

Completion Rate

74/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Comanche Biopharma

1 program

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 1L

La Jolla Pharmaceutical Company

1 program

Phase 1M

Metro International Biotech, LLC

1 program

Phase 1P

Pascoe Pharmazeutische Praeparate GmbH

1 program

Phase 1AstraZeneca logo

AstraZeneca

3 programs

Phase 2

Pipeline

Programs by Phase

Preclinical21

Calcium

Eli Lilly

Carbetocin

ACADIA Pharmaceuticals Inc.

Diltiazem

Bausch Health Americas, Inc.

Irbesartan

Sanofi

Mgso4

Services Institute of Medical Sciences, Pakistan

Phase 111

Losartan Potassium

Merck & Co.

Salsalate

Joslin Diabetes Center

Labetalol

Alvogen Korea

Angiotensin II

La Jolla Pharmaceutical Company

Eplerenone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 213

Chlorthalidone

Alnylam Pharmaceuticals

Ravulizumab

AstraZeneca

Sildenafil

Viatris Specialty LLC

Rosuvastatin

AstraZeneca

Oxycodone

Protega

Phase 316

Hydroxychloroquine

Alnylam Pharmaceuticals

Pravastatin

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Oxytocin

Retrophin

Esomeprazole

Dexcel Pharma Technologies Ltd.

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved33

Magnesium Sulfate

Fresenius Kabi Oncology Ltd.

Misoprostol

Pfizer

Nifedipine

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Hydrochlorothiazide

AbbVie

Acetaminophen

Kenvue Brands

Analysis

Modality Breakdown

97%

Small molecule

104 of 107 classified programs — the dominant modality here.

3%ALL OTHERSMonoclonal antibody22%Vaccine1<1%

Small molecule leads; the ring shows all 107 classified programs, each share of the total. Modality classified for 97% of 118 pipeline programs.

Analysis

Trial Status

158

clinical trials

Completed65 · 41%
Unknown status29 · 18%
Recruiting21 · 13%
Not yet recruiting16 · 10%
Terminated14 · 9%
Withdrawn7 · 4%
Other6 · 4%

Clinical Trials

Trial Activity

158 trials

Aspirin for Postpartum Patients With Preeclampsia
Recruiting·MMemorialCare Health System·Phase 2·NCT05924971·86 enrolled
Vascular Effects of High-Salt After Preeclampsia
Recruiting·—·Phase 1·NCT06749418·40 enrolled
The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for Preeclampsia
Recruiting·—·Phase 3·NCT05287321·58 enrolled
Predictors of Aspirin Failure in Preeclampsia Prevention
Recruiting·RRockefeller University·Phase 1·NCT05709483·130 enrolled
Aspirin and Preeclampsia
Recruiting·UUniversity of Chicago·Phase 4·NCT04479072·180 enrolled
The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.
Recruiting·UUniversity of Alabama at Birmingham·N/A·NCT05676476·132 enrolled
Screening for Preeclampsia in Norway With Aspirin Discontinuation at 24-28 Weeks
Recruiting·SSt. Olavs Hospital·N/A·NCT06108947·300 enrolled
Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology
Recruiting·UUniversity Hospital, Toulouse·Phase 3·NCT05625724·1,164 enrolled
Aspirin Discontinuation in High-Risk Pregnant Women of Preeclampsia
Recruiting·FFANG HE·Phase 3·NCT06111079·1,800 enrolled
Vitamin D for Preventing Recurrent Preeclampsia in Pregnant Women
Recruiting·NNishtar Medical University·Phase 4·NCT07288801·146 enrolled
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
Recruiting·UUniversity of Pennsylvania·Phase 3·NCT06408181·1,150 enrolled
Postpartum Low-Dose Aspirin and Preeclampsia
Recruiting·—·Phase 2·NCT03667326·100 enrolled
Treatment With Aspirin After Preeclampsia: TAP Trial
Recruiting·—·Phase 4·NCT06281665·60 enrolled
Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia
Recruiting·UUniversity of Mississippi Medical Center·Phase 2·NCT02989025·60 enrolled
LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention
Recruiting·—·Phase 4·NCT07361679·100 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)